Cytochrome P450 Directed Prodrug Activation Therapy in Research of Cancer Enzymology  

肿瘤酶学研究中细胞色素P450活化前体药物的基因治疗(英文)

作　　者：周江泉[1] 汤致强[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院药剂科,北京100021

出　　处：《Journal of Chinese Pharmaceutical Sciences》2005年第1期1-9,共9页中国药学（英文版）

摘　　要：Cancer enzymology is a promising filiation of bio-medical sciences. In thepast decades, enzymes, such as GST(glutathione S-transferase) , PKC(protein kinase C) , Topo(DNAtopoisomerases), TK(tyrosine kinase), CD (bacterial cytosine deaminase), CPG2(carboxypeptidase G2) ,and PNP (purine nucleoside phosphorylase), have been known to bear close relations to cancer. Theirspecific expression and influence on the process of tumor initiation, promotion and progressionattract scientists to apply them as a biochemical marker of certain malignant tumor, a predictor ofresponse in cancer chemotherapy; to apply them to drug design, tumor prevention and as adjuvant toradiotherapy or surgery.肿瘤酶学在肿瘤基因治疗中发挥着重要的基础作用。其中对细胞色素P4 5 0酶的研究可促进深入理解肿瘤的生物学特性和优化肿瘤治疗方案。转载酶基因 /前体药物治疗的实验室和临床研究极大的推动了它的发展和应用。前体药物在肿瘤生理环境下 ,由肿瘤内特异表达的P4 5 0酶或转载的P4 5 0酶代谢活化。本文对细胞色素P4 5 0活化前体药物的基因治疗方法中诸如结构和功能关系、药动学参数、特异性载体、乏氧环境 ,细胞调亡以及临床用药顺序和剂量等各种影响因素的进展进行了综述 .

关 键 词：cytochrome P450 cancer enzymology gene directed enzyme prodrug therapy(GDEPT) structure-function relationship selective delivery 

分 类 号：R730.5[医药卫生—肿瘤]